Streetbeat News

Stock Prices

SRCL

Stericycle's stock trades lower following the announcement of Q2 revenue results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 4:06 pm

CACI

CACI International's shares surged following the announcement of its Q3 financial results, which exceeded expectations. Additionally, the company uplifted its FY24 revenue guidance, surpassing analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 4:05 pm

ATNI

HTZ

MRK

ORN

PCSA

PI

ULBI

U.S. stocks traded lower, with the S&P 500, Nasdaq, and Dow all experiencing declines. Merck & Co. raised its 2024 outlook after reporting strong Q1 financial results. Impinj, Ultralife Corporation, and Processa Pharmaceuticals saw significant stock increases after positive financial reports, while ATN International, Hertz Global Holdings, and Orion Group Holdings faced declines due to disappointing financial performances.

Portfolio Pulse from Avi Kapoor

April 25, 2024 | 4:04 pm

PFSI

PennyMac Financial Services (PFSI) shares dropped following the announcement of Q1 sales results that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 4:02 pm

ABG

Asbury Automotive Group Inc (NYSE:ABG) shares fell over 3.4% after reporting Q1 earnings per share of $7.21, missing estimates of $7.76, amid a tight inventory market and volume challenges. Quarterly sales were $4.201 billion, below expectations of $4.264 billion, but revenue increased 17% year over year. Gross profit rose 8% to $750 million, though gross margin dropped to 17.9%. The company also repurchased 240,000 shares for $50 million during Q1.

Portfolio Pulse from Nabaparna Bhattacharya

April 25, 2024 | 4:01 pm

PFSI

PennyMac Financial Services (PFSI) reported Q1 2024 earnings with an adjusted EPS of $2.48, surpassing the $2.31 estimate. However, their sales of $305.660M fell short of the expected $432.416M, marking a 29.31% miss but a 0.92% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 4:01 pm

WEX

WEX shares declined following the announcement of disappointing Q1 financial results and the provision of Q2 adjusted EPS guidance that fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 4:01 pm

MSTR

MicroStrategy (NASDAQ:MSTR) has received mixed analyst ratings, with a recent shift towards more bullish perspectives. The average 12-month price target for MSTR has been raised to $1740.0, indicating a significant potential upside. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their response to MicroStrategy's performance and market conditions. Despite facing a revenue decline of -6.09% in the last quarter, MicroStrategy's financial indicators such as net margin and ROE remain strong, although its ROA and debt management pose challenges.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 4:01 pm

BMRN

In the past three months, 8 analysts have provided ratings for Biomarin Pharmaceutical (NASDAQ:BMRN), with a mix of somewhat bullish and indifferent perspectives. The average 12-month price target is $100.88, down from $106.25. Analyst actions include maintaining, raising, and lowering ratings and price targets. BioMarin focuses on rare-disease therapies and has seen a revenue growth of 20.22% as of December 31, 2023, but lags in profitability and efficiency metrics compared to industry peers.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 4:01 pm

FTV

Fortive (NYSE:FTV) received mixed analyst ratings with a shift towards a more neutral stance in the latest quarter. The average 12-month price target for FTV has been raised to $88.6, reflecting a 4.1% increase from the previous target. Analyst actions include both upgrades and downgrades, with notable firms like RBC Capital, Wells Fargo, JP Morgan, Citigroup, Barclays, Truist Securities, and Mizuho involved. Fortive, a diversified industrial technology firm, reported a revenue of $6.1 billion in 2023, with a net margin of 16.75% but lower ROE and ROA compared to industry standards.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 4:00 pm